The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors - Test2 - elhamkhani - TriplyDB

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

http://www.wikidata.org/entity/Q27485895

about

Virologic Tools for HCV Drug Resistance Testing Chutes and ladders in hepatitis C nucleoside drug development Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796 The Octadecyloxyethyl Ester of (S)-9-[3-Hydroxy-2-(Phosphonomethoxy) Propyl]Adenine Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication in Genotype 1A, 1B, and 2A Replicons Slow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C Virus Proanthocyanidin from Blueberry Leaves Suppresses Expression of Subgenomic Hepatitis C Virus RNA Development of a Cell-Based Hepatitis C Virus Infection Fluorescent Resonance Energy Transfer Assay for High-Throughput Antiviral Compound Screening Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication Mechanisms of activity and inhibition of the hepatitis C virus RNA-dependent RNA polymerase.Inhibitors of the tick-borne, hemorrhagic fever-associated flaviviruses.Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis Rapid emergence of protease inhibitor resistance in hepatitis C virus.Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052 INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661.Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication Antiviral efficacy upon administration of a HepDirect prodrug of 2'-C-methylcytidine to hepatitis C virus-infected chimpanzees.Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.Use of illumina deep sequencing technology to differentiate hepatitis C virus variants.Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection.NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase.Sofosbuvir and ABT-450: terminator of hepatitis C virus?Anti-HCV drugs in the pipeline.Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.

P2860

Q26774374-9E59FA44-B254-4F10-9082-AA52FFD49CBC Q26998630-A35C7CA3-2B35-4508-9853-64CAC1D89BCE Q27487769-62C79E15-CA31-4799-86D7-7B8C509A22B4 Q27487949-5A0E574A-8D49-4D26-B322-CDB2D39104D0 Q27488386-7AE75BBE-74D8-40AD-B953-3FFD1A49996A Q27488429-E319FA07-B9C9-4F2F-A8E4-02F5862B10EA Q27488887-9E631F5A-3934-43F2-9719-1E28FD8F0714 Q27489836-0E54A751-2B81-4DAF-917A-67134DC86E98 Q27490187-ADB6A75C-B18C-4A4B-9075-95F098C38D11 Q27490222-938EC801-3DA0-4069-8144-01112E2D9933 Q27490426-FC082180-563A-4116-BF46-FFEE9DBFEFDA Q28481489-1FDF58F7-DDA1-4000-9E7C-A23918EF4221 Q28536780-E6A9996E-5BAA-4839-B8E6-D38BDB7BE3FE Q30318760-8A07301A-F3CC-4FBD-904E-FE9082CAF7E7 Q33798180-F3648368-5751-4464-B8C9-498C254D8C7E Q33899320-D54BD345-4896-4B43-98A2-3C63476D149C Q34045444-CE0361D5-A1A1-4D68-96CB-04F208FFCBEC Q34184046-8056120C-7E06-456B-A850-84C0862E4A2E Q34409020-E072406F-71B8-4CD2-9917-D7F1B43D4C3A Q34483468-3EBB5B52-CB4D-4C4D-B2FB-2A3765C51A64 Q34489239-D54A1D3E-1A97-4BF2-9E85-744A6A7AEE64 Q34533176-67A36028-DBFB-47C5-8FEE-83E652DEA9A5 Q34551913-2C162B0D-F4B8-494F-B34C-91004B665503 Q34634791-624B916C-633F-4A90-A28C-291E1EA1235C Q34933094-2A30EF01-8CD7-4558-B45F-BEFBC557EA23 Q34957256-5B17B7F7-18E7-49EB-BDDB-465ADE12A253 Q35004972-BD63645A-2777-4BD4-99BD-EDCBC206FF2D Q35008754-5D4CEA21-6730-4E77-A739-0D6AA8AE1C2E Q35103718-A5C688BB-683C-414B-9E39-8CB24ECB0EC9 Q35116027-B449F050-9A61-40E9-8435-3366B51BEEFE Q35139479-CD5E4474-7FE1-43C4-8437-86E20E7C7633 Q35260330-BFC6327B-8CDB-47B6-A624-6902A226CDC7 Q35653358-5BD292D2-7739-44D4-93CF-179CE2082A6A Q35806939-839D4AE5-B9BE-4F56-A953-EB9A461DF6A4 Q36104288-B8865376-0359-44A9-963E-DEE6840F932B Q36396219-6B892784-5785-44E7-B8B2-A6DCD13FC00C Q36583173-0121422C-0444-4597-BD16-28080C4FE102 Q36897890-ECC80A72-4455-421C-9462-4823528840C7 Q37177740-B07EA0B2-C152-4D61-92C0-3A2B03FF939A Q37313166-AE16366A-3F82-462B-BBA3-2CCEBA0B7A51

P2860

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

http://www.wikidata.org/entity/Q27485895

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

The Hepatitis C Virus Replicon ...... ymerase or Protease Inhibitors

@ast

The Hepatitis C Virus Replicon ...... ymerase or Protease Inhibitors

@en

The Hepatitis C Virus Replicon ...... ymerase or Protease Inhibitors

@nl

type

label

The Hepatitis C Virus Replicon ...... ymerase or Protease Inhibitors

@ast

The Hepatitis C Virus Replicon ...... ymerase or Protease Inhibitors

@en

The Hepatitis C Virus Replicon ...... ymerase or Protease Inhibitors

@nl

prefLabel

The Hepatitis C Virus Replicon ...... ymerase or Protease Inhibitors

@ast

The Hepatitis C Virus Replicon ...... ymerase or Protease Inhibitors

@en

The Hepatitis C Virus Replicon ...... ymerase or Protease Inhibitors

@nl

P1433

Q27485895-C45E6B04-4EE4-4753-8F76-7402FF7319B3

P1476

Q27485895-4108C29A-4690-48E0-BDAA-A1FCCC984842

P2093

Q27485895-0A2D7390-C987-423A-A5F5-E54D3D88F63B

Q27485895-10B0B238-7181-43CB-A484-2175BB42617C

Q27485895-14AB9F1F-215F-4532-A160-0F528D0E60D8

Q27485895-3BEE619F-9FD7-4AAF-90A5-D552C516E30A

Q27485895-465BE940-95FE-4166-B226-F56289D244CD

Q27485895-8FC4659E-83B3-4D8A-935B-D857A7A4379C

Q27485895-9FA69B43-9134-43F5-BC59-A11537FA04D4

Q27485895-D942F33E-5A9F-44A9-870A-C18922701DE3

Q27485895-DEEDBC04-AA9B-4F95-8CA1-C1679C7D9875

P2860

Q27485895-01C473A9-236E-47E2-97D5-1BF79C85FF06

Q27485895-04BEA82F-C625-408F-B97A-F77846465DF5

Q27485895-0669AEB6-2AF4-4D98-BE82-A536DDF6A263

Q27485895-0E59A197-9995-4A9E-BAEF-D87CEE1D4A45

Q27485895-13F95F49-1CE1-4D48-8862-F3405735E78A

Q27485895-2307D4A5-D142-48F4-AC4B-1F7436BAD011

Q27485895-3390F80C-8C59-48F7-8B08-3E8CD49006D6

Q27485895-3506DB24-38AC-4B6C-BB44-708D13B42AA8

Q27485895-3D78CC62-5ED8-45D0-A981-72641AFB79FB

Q27485895-5E22D02C-3A16-4EB5-8740-73C1587F1D43

P304

Q27485895-8288081E-F660-4C2D-8210-CECDFAFE07EE

P31

Q27485895-A8F9A10A-9629-42D8-9CD7-6CB7AA592199

P356

Q27485895-6225D1D3-CE68-4168-8632-BBE563D7D49F

P407

Q27485895-973294B1-6C17-42F4-894B-E0261AEAE896

P433

Q27485895-E4914DBD-E8C2-4BD9-AA46-E2265EDB8D3E

P478

Q27485895-57D1DBEA-28A2-4B1D-8066-F35B67C1A4C8

P577

Q27485895-F59F7F92-D1F7-4ADF-82BF-4422034AEE0A

P698

Q27485895-BB6776F8-EA93-40F4-BDE4-4E7A0FB7220A

P932

Q27485895-F68D7255-DAD4-4F5C-A6CB-12B471F500E1

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

The Hepatitis C Virus Replicon ...... ymerase or Protease Inhibitors

@en

P2093

Hyunsoon Kang

http://www.w3.org/2001/XMLSchema#string

Isabel Najera

http://www.w3.org/2001/XMLSchema#string

Julian Symons

http://www.w3.org/2001/XMLSchema#string

Matthew F McCown

http://www.w3.org/2001/XMLSchema#string

Nick Cammack

http://www.w3.org/2001/XMLSchema#string

Samir Ali

http://www.w3.org/2001/XMLSchema#string

Sonal Rajyaguru

http://www.w3.org/2001/XMLSchema#string

Sophie Le Pogam

http://www.w3.org/2001/XMLSchema#string

Wen-Rong Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations.

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor

Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell Culture

The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells

Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

P304

1604-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01317-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18285474

http://www.w3.org/2001/XMLSchema#string

P932

2346640

http://www.w3.org/2001/XMLSchema#string